GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis.

On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...

California biotech NGM Bio is slimming down as the company pivots focus, shedding around 75% of staff, pausing development of ...

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced two-year results from the open-label arm of ...

Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to ...

Two patients with MASH share their paths to diagnosis, including the challenges they faced and what it took to find answers.

Data presentation included efficacy and biomarker analyses from the NAVIGATE trial (n=287). Belapectin 2 mg/kg demonstrated a statistically significant reduction in new varices at 18 months in the per ...

Analysts anticipate Altimmune to report an earnings per share (EPS) of $-0.34. The announcement from Altimmune is eagerly anticipated, with investors seeking news of surpassing estimates and favorable ...

For patients with metabolic dysfunction-associated steatohepatitis and fibrosis, semaglutide is associated with improved liver histologic outcomes.

The single-celled parasite Entamoeba histolytica infects 50 million people each year, killing nearly 70,000. Usually, this wily, shape-shifting amoeba causes nothing worse than diarrhea.